Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression

Endocrinology

Volumn 154, Issue 1, 2013, Pages 25-35

  Kim, Won Gu ^a   Zhu, Xuguang ^a   Kim, Dong Wook ^a   Zhang, Lisa ^a   Kebebew, Electron ^a   Cheng, Sheue Yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; THYROID HORMONE RECEPTOR BETA; ZEBULARINE;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CYTIDINE; DNA METHYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID HORMONE RECEPTORS BETA; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871696473     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1728     Document Type: Article

References (36)

1. Yen PM 2001 Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097-1142 (Pubitemid 32606667)
2. Cheng SY, Leonard JL, Davis PJ 2010 Molecular aspects of thyroid hormone actions. Endocr Rev 31:139-170
3. Lin KH, Shieh HY, Chen SL, Hsu HC 1999 Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 26:53-61
4. Ando S, Sarlis NJ, Oldfield EH, Yen PM 2001 Somatic mutation of TRβ can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 86:5572-5576 (Pubitemid 33070290)
5. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY, Nauman A 2002 Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis 23:25-33 (Pubitemid 34213548)
6. Silva JM, Domínguez G, González-Sancho JM, García JM, Silva J, García-Andrade C, Navarro A, Muñoz A, Bonilla F 2002 Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21:4307-4316 (Pubitemid 34753837)
7. Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA, Kazlauskaite R, Pankratz DG, Wynshaw-Boris A, Refetoff S, Weintraub B, Willingham MC, Barlow C, Cheng S 2000 Mice with a targeted mutation in the thyroid hormone β receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA 97:13209-13214
8. Li Z, Meng ZH, Chandrasekaran R, Kuo WL, Collins CC, Gray JW, Dairkee SH 2002 Biallelic inactivation of the thyroid hormone receptor β1 gene in early stage breast cancer. Cancer Res 62:1939-1943 (Pubitemid 34408433)
9. Iwasaki Y, Sunaga N, Tomizawa Y, Imai H, Iijima H, Yanagitani N, Horiguchi K, Yamada M, Mori M 2010 Epigenetic inactivation of the thyroid hormone receptor β1 gene at 3p24.2 in lung cancer. Ann Surg Oncol 17:2222-2228
10. Ling Y, Xu X, Hao J, Ling X, Du X, Liu X, Zhao X 2010 Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients. Cancer Genet Cytogenet 196:140-145
11. Joseph B, Ji M, Liu D, Hou P, Xing M 2007 Lack of mutations in the thyroid hormone receptor (TR) α and β genes but frequent hypermethylation of the TRβ gene in differentiated thyroid tumors. J Clin Endocrinol Metab 92:4766-4770 (Pubitemid 350223458)
12. Hörkkö TT, Tuppurainen K, George SM, Jernvall P, Karttunen TJ, Mäkinen MJ 2006 Thyroid hormone receptor β1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations. Int J Cancer 118:1653-1659 (Pubitemid 43376428)
13. Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, Catchpoole D, Chiaramonte R, Brini AT, Griffiths M, Maher ER, Zabarovsky E, Latif F 2009 Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics 4:185-193
14. Jazdzewski K, Boguslawska J, Jendrzejewski J, Liyanarachchi S, Pachucki J, Wardyn KA, Nauman A, de la Chapelle A 2011 Thyroid hormone receptor β (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab 96:E546-E553
15. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N, Zhang Y 2009 International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20:525-531
16. Kondo T, Ezzat S, Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306
17. Russo D, Damante G, Puxeddu E, Durante C, Filetti S 2011 Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol 46:R73-R81
18. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M 2007 Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 212:330-344 (Pubitemid 47025622)
19. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, Nakamura N, Yamane T, Kobayashi M, Katoh R 2009 Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest 89:791-799
20. Zuo H, Gandhi M, Edreira MM, Hochbaum D, Nimgaonkar VL, Zhang P, Dipaola J, Evdokimova V, Altschuler DL, Nikiforov YE 2010 Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res 70:1389-1397
21. Vivaldi A, Miasaki FY, Ciampi R, Agate L, Collecchi P, Capodanno A, Pinchera A, Elisei R 2009 Re-differentiation of thyroid carcinoma cell lines treated with 5-aza-2′-deoxycytidine and retinoic acid. Mol Cell Endocrinol 307:142-148
22. Miasaki FY, Vivaldi A, Ciampi R, Agate L, Collecchi P, Capodanno A, Pinchera A, Elisei R 2008 Retinoic acid receptor β2 reexpression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2′-deoxycytidine treatment. J Endocrinol Invest 31:724-730
23. Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS, Willingham MC, Cheng SY 2005 An unliganded thyroid hormone β receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol 25:124-135 (Pubitemid 40039805)
24. Bhat MK, McPhie P, Cheng SY 1995 Interaction of thyroid hormone nuclear receptor with antibody: characterization of the thyroid hormone binding site. Biochem Biophys Res Commun 210:464-471
25. Martinez E, Palhan VB, Tjernberg A, Lymar ES, Gamper AM, Kundu TK, Chait BT, Roeder RG 2001 Human STAGA complex is a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors in vivo. Mol Cell Biol 21:6782-6795 (Pubitemid 32911240)
26. Ying H, Furuya F, Zhao L, Araki O, West BL, Hanover JA, Willingham MC, Cheng SY 2006 Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone β receptor inhibits mitotic progression. J Clin Invest 116:2972-2984 (Pubitemid 44684482)
27. Kim WG, Guigon CJ, Fozzatti L, Park JW, Lu C, Willingham MC, Cheng SY 2012 SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin Cancer Res 18:1281-1290
28. Ambroziak M, Pachucki J, Stachlewska-Nasfeter E, Nauman J, Nauman A 2005 Disturbed expression of type 1 and type 2 iodothyronine deiodinase as well as titf1/nkx2-1 and pax-8 transcription factor genes in papillary thyroid cancer. Thyroid 15:1137-1146 (Pubitemid 41720720)
29. Polakis P 2007 The many ways of Wnt in cancer. Curr Opin Genet Dev 17:45-51 (Pubitemid 46109296)
30. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL 1999 Frequent mutation and nuclear localization of β-catenin in anaplastic thyroid carcinoma. Cancer Res 59:1811-1815 (Pubitemid 29186147)
31. Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY 2008 Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol 28:4598-4608 (Pubitemid 351977757)
32. Zhu XG, Zhao L, Willingham MC, Cheng SY 2010 Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma. Oncogene 29:1909-1919
33. Yang X, Lay F, Han H, Jones PA 2010 Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 31:536-546
34. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM 1986 Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46:4831-4836 (Pubitemid 16000370)
35. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T, Jones PA 2004 Preferential response of cancer cells to zebularine. Cancer Cell 6:151-158 (Pubitemid 39485687)
36. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP 2002 Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321:591-599 (Pubitemid 36124798)